Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Turning into a Distributed Writer: My Composing Process - 2Find Wonderful Stream Voyage Objections On the planet
- 3Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- 4Federal judge upholds Hawaii's new climate change tax on cruise passengers
- 5Italy's Beloved Trevi Fountain Hides A Unique Secret That Can Be Explored Underground
- Protester climbs on to balcony of Iranian embassy in London
- Pick Your Favored method of transportation
- Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- The beauty advent calendar boom is here. Sephora kids are all in.
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- Investigating the Medical advantages of Aloe Vera
- Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare
- The hunt for dark matter: a trivia quiz
- What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
